Clinical Trial Update: Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome [Phase 2]

View source ↗

Summary

Phase IIa trial of ALXN1007 for non-criteria manifestations of antiphospholipid syndrome was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome

Drugs mentioned

• ALXN1007

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Antiphospholipid (aPL)-Positive | Phase 2 | Status: TERMINATED | Results posted: 2017-07-13